The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
Open accessAbstract
Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2-agonist bronchodilator recently approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). The aim of the present study was to investigate the efficacy and safety of indacaterol compared with placebo and the twice-daily β 2-agonist, salmeterol, as an active control. Patients with moderate-to-severe COPD were randomised to 6 months double-blind treatment with indacaterol (150 μg once daily), salmeterol (50 μg twice daily) or placebo. The primary efficacy end-point was trough (24 h post-dose) forced expiratory volume in 1 s (FEV 1) after 12 weeks. 1,002 patients were randomised and 838 (84%) completed the study. Indacaterol increased trough FEV 1 at week 12 by 170 mL over placebo (p<0.001) and by 60 mL over salmeterol (p<0.001). Both active treatments improved health status (St George's Respiratory Questionnaire) and dyspnoea (transition dyspnoea index) compared with placebo, with differences between them favouring indacaterol. Safety profiles were similar across the treatment groups, and both indacaterol and salmeterol were well tolerated. Once-daily treatment with 150 μg indacaterol had a significant and clinically relevant bronchodilator effect over 24 h post-dose and improved health status and dyspnoea to a greater extent than twice-daily 50 μg salmeterol. Indacaterol should prove a useful additional treatment for patients with COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
Mortality in COPD: role of comorbidities
Sin, D. D., Anthonisen, N. R., Soriano, J. B., & Agusti, A. G. (2006) · European Respiratory Journal · doi:10.1183/09031936.00133805 · Cited by 1,052
Cited by
Cavaillès, A., Brinchault-Rabin, G., Dixmier, A., Goupil, F., Gut-Gobert, C., Marchand-Adam, S., Meurice, J.-C., Morel, H., Person-Tacnet, C., Leroyer, C., et al. (2013) · European Respiratory Review · doi:10.1183/09059180.00008612 · Cited by 510
Pharmacology and Therapeutics of Bronchodilators
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004580 · Cited by 467
Metadata
- Authors
- Kornmann, O., Dahl, R., Centanni, S., Dogra, A., Owen, R., Lassen, C., & Kramer, B.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2010-08-06
- Volume
- 37
- Issue
- 2
- Pages
- 273-279
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2130703359
- Cited by
- 213
- References
- 4
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. https://app.cochat.ai/papers/10.1183/09031936.00045810
- The paper
- Kornmann, O., Dahl, R., Centanni, S., Dogra, A., Owen, R., Lassen, C., & Kramer, B. (2011). Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. European Respiratory Journal. https://doi.org/10.1183/09031936.00045810
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.